This company seems to have been delisted
Reason: Acquired by LG Chem
Last recorded trade on: March 24, 2023
Source: http://investor.aveooncology.com/news-releases/news-release-details/lg-chem-completes-acquisition-aveo-oncology
Reason: Acquired by LG Chem
Last recorded trade on: March 24, 2023
Source: http://investor.aveooncology.com/news-releases/news-release-details/lg-chem-completes-acquisition-aveo-oncology
AVEO Oncology
AVEO
C$20.52
Share price
0.00%
Change (1 day)
171.92%
Change (1 year)
Categories
AVEO Oncology (AVEO) - Total liabilities
Total liabilities on the balance sheet as of September 2022 : C$99.04 Million
According to AVEO Oncology 's latest financial reports the company's total liabilities are C$99.04 Million. A company’s total liabilities is the sum of all current and non-current debts and obligations.
AVEO Oncology - Total liabilities on balance sheet (from 2008 to 2022)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2021-12-31 | C$75.79 M | 88% |
| 2020-12-31 | C$40.31 M | -13.67% |
| 2019-12-31 | C$46.69 M | -37.85% |
| 2018-12-31 | C$75.14 M | -34.29% |
| 2017-12-31 | C$0.11 B | 191.36% |
| 2016-12-31 | C$39.25 M | 21.36% |
| 2015-12-31 | C$32.34 M | -44.32% |
| 2014-12-31 | C$58.08 M | -28.58% |
| 2013-12-31 | C$81.33 M | -7.61% |
| 2012-12-31 | C$88.03 M | 21.03% |
| 2011-12-31 | C$72.73 M | -8.21% |
| 2010-12-31 | C$79.24 M | 4.65% |
| 2009-12-31 | C$75.72 M | -63.1% |
| 2008-12-31 | C$0.20 B | 23.84% |
| 2007-12-31 | C$0.16 B |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Biogen BIIB | C$15.12 B | 15,171.04% | 🇺🇸 USA |
 Regeneron Pharmaceuticals REGN | C$11.16 B | 11,169.27% | 🇺🇸 USA |
 Merrimack Pharmaceuticals MACK | C$31.01 M | -68.68% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | C$102.58 B | 103,479.32% | 🇺🇸 USA |
 Eli Lilly LLY | C$100.62 B | 101,494.19% | 🇺🇸 USA |
 Amgen AMGN | C$113.77 B | 114,780.92% | 🇺🇸 USA |